Dr. Yardley on Unmet Need for Patients With HER2+ Breast Cancer

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses unmet treatment needs for patients with HER2-positive breast cancer.

Several developments have been made in the field of HER2-positive breast cancer, particularly with the additions of trastuzumab (Herceptin) and pertuzumab (Perjeta).

However, researchers are trying to expand the number of HER2 agents available for these patients, Yardley explains, which are being explored in ongoing clinical trials.